Header Logo

Connection

MOHAMMED N AL HALLAK to Antineoplastic Agents, Immunological

Back to Details
This is a "connection" page, showing publications MOHAMMED N AL HALLAK has written about Antineoplastic Agents, Immunological.
MOHAMMED N AL HALLAK
Connection Strength
0.029
Antineoplastic Agents, Immunological
  1. The phase I/II eNRGy trial: Zenocutuzumab in?patients with cancers harboring NRG1 gene fusions. Future Oncol. 2024; 20(16):1057-1067.
    View in: PubMed
    Score: 0.029
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.